A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours

por Robbrecht, Debbie G. J., Lopez, Juanita, Calvo, Emiliano, He, Xiaomin, Hiroshi, Hirai, Soni, Nital, Cook, Natalie, Dowlati, Afshin, Fasolo, Angelica, Moreno, Victor, Eskens, Ferry A. L. M., de Bono, Johann S.
Publicado 2020

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

por Decaens, Thomas, Barone, Carlo, Assenat, Eric, Wermke, Martin, Fasolo, Angelica, Merle, Philippe, Blanc, Jean-Frédéric, Grando, Véronique, Iacobellis, Angelo, Villa, Erica, Trojan, Joerg, Straub, Josef, Bruns, Rolf, Berghoff, Karin, Scheele, Juergen, Raymond, Eric, Faivre, Sandrine
Publicado 2021

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

por Decaens, Thomas, Barone, Carlo, Assenat, Eric, Wermke, Martin, Fasolo, Angelica, Merle, Philippe, Blanc, Jean-Frédéric, Grando, Véronique, Iacobellis, Angelo, Villa, Erica, Trojan, Joerg, Straub, Josef, Bruns, Rolf, Berghoff, Karin, Scheele, Juergen, Raymond, Eric, Faivre, Sandrine
Publicado 2021

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

por Bianchini, Giampaolo, Pusztai, Lajos, Karn, Thomas, Iwamoto, Takayuki, Rody, Achim, Kelly, Catherine M, Müller, Volkmar, Schmidt, Marcus, Qi, Yuan, Holtrich, Uwe, Becker, Sven, Santarpia, Libero, Fasolo, Angelica, Del Conte, Gianluca, Zambetti, Milvia, Sotiriou, Christos, Haibe-Kains, Benjamin, Symmans, W Fraser, Gianni, Luca
Publicado 2013

PD-1 Blockade in Anaplastic Thyroid Carcinoma

por Capdevila, Jaume, Wirth, Lori J., Ernst, Thomas, Ponce Aix, Santiago, Lin, Chia-Chi, Ramlau, Rodryg, Butler, Marcus O., Delord, Jean-Pierre, Gelderblom, Hans, Ascierto, Paolo A., Fasolo, Angelica, Führer, Dagmar, Hütter-Krönke, Marie Luise, Forde, Patrick M., Wrona, Anna, Santoro, Armando, Sadow, Peter M., Szpakowski, Sebastian, Wu, Hongqian, Bostel, Geraldine, Faris, Jason, Cameron, Scott, Varga, Andreea, Taylor, Matthew
Publicado 2020

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

por Chan, Stephen L., Schuler, Martin, Kang, Yoon-Koo, Yen, Chia-Jui, Edeline, Julien, Choo, Su Pin, Lin, Chia-Chi, Okusaka, Takuji, Weiss, Karl-Heinz, Macarulla, Teresa, Cattan, Stéphane, Blanc, Jean-Frederic, Lee, Kyung-Hun, Maur, Michela, Pant, Shubham, Kudo, Masatoshi, Assenat, Eric, Zhu, Andrew X., Yau, Thomas, Lim, Ho Yeong, Bruix, Jordi, Geier, Andreas, Guillén-Ponce, Carmen, Fasolo, Angelica, Finn, Richard S., Fan, Jia, Vogel, Arndt, Qin, Shukui, Riester, Markus, Katsanou, Vasiliki, Chaudhari, Monica, Kakizume, Tomoyuki, Gu, Yi, Porta, Diana Graus, Myers, Andrea, Delord, Jean-Pierre
Publicado 2022